Eli Lilly and Company announced plans to build a $5B manufacturing facility in Virginia, marking one of the largest single investments in the state’s history. The move underscores Lilly’s continued expansion of its U.S. production capacity to meet surging demand for its diabetes and weight management treatments, including incretin-based therapies.
The new site, expected to create several thousand construction jobs and more than 1,000 permanent positions once operational, will focus on advanced biomanufacturing and large-scale production of injectable medicines. Virginia officials, who worked closely with Lilly to secure the investment, described the project as a transformational economic development win for the region.
Lilly’s commitment follows a wave of biopharma manufacturing announcements across the U.S. as companies seek to strengthen supply chains while scaling up output for complex biologics. For patients, the facility is expected to help ensure more reliable access to high-demand medications, with production anticipated to begin later this decade.
“Virginia offers the infrastructure, workforce, and innovation ecosystem needed to support Lilly’s mission,” said company representatives. The investment reflects both the increasing importance of U.S.-based production and the continued growth of Lilly’s market-leading therapeutic portfolio.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!